Milestone Pharmaceuticals Inc.(MIST)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Milestone Pharmaceuticals Inc. (MIST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MIST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Milestone Pharmaceuticals Inc. reports quarterly revenue of $559.0K, net income of $-28.6M, free cash flow of $-22.7M. Top institutional holders of MIST by reported 13-F value include Pavaki Capital Management, RTW INVESTMENTS, Propel Bio Management, based on the most recent SEC filings. MIST trades on the Nasdaq exchange and files with the SEC under CIK 1408443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Milestone Pharmaceuticals Inc. directly from SEC EDGAR.

Revenue

$559.0K

Net Income

$-28.6M

Free Cash Flow

$-22.7M

Institutions holding MIST

Institutional investors reporting a position in Milestone Pharmaceuticals Inc. on SEC Form 13F.
InstitutionSharesValueReported
Pavaki Capital Management9,067,848$12.2M2026-06-30
RTW INVESTMENTS7,833,336$10.5M2026-06-30
Propel Bio Management7,429,590$10.0M2026-06-30
Point72 Asset Management, L.P.5,411,138$7.3M2026-06-30
Simplify Asset Management3,349,379$4.5M2026-06-30
MILLENNIUM MANAGEMENT3,142,219$4.2M2026-06-30
TWO SIGMA INVESTMENTS2,040,015$2.7M2026-06-30
MARSHALL WACE, LLP1,797,695$2.4M2026-06-30
Kalehua Capital Management1,269,237$1.7M2026-06-30
Lion Point Capital820,000$1.1M2026-06-30
MIST

Milestone Pharmaceuticals Inc.

MIST
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$559.0K

Net Income

Q2 2026
EDGAR

$-28.61M

EPS (Diluted)

Q2 2026
EDGAR

$-0.21

Free Cash Flow

Q2 2026
EDGAR

$-22.74M

Debt/Equity

Q2 2026
EDGAR

3.25

Top Institutional Holders

as of Q2 2026
$66.81M total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…